STUDY ON SHORT-TERM AND LASTING CLINICAL BENEFIT AFTER 3 YEARS OF IMMUNOTHERAPY WITH GRASSPOLLEN DEPOT ALLERGOID (ALLERGOVIT)

Alum-adsorbed allergoid preparations have been on the market for more than 7 years with a short-course dosage schedule. The success of this form of therapy, including patient compliance, has been investigated i n a multicentre retrospective study. On the basis of data from 278 pat ients it was shown that 85% of the patients that had completed 3 years immunotherapy achieved a good or very good improvement. These short-t erm results are consistent with reports from earlier controlled clinic al trials. The lasting benefit of this causal therapy conducted in 3 c onsecutive years was apparent in 85% of the patients an average of 3 y ears later. Therefore, this immunotherapy can lead to good clinical im provement and economizes on both costs and time through a reduction in the need for antiallergic medication and the use of a short-term dosa ge schedule.